AstraZeneca Extends Oncology Collaboration with Tempus AI via $200M Agreement

Tempus AI (TEM) has announced a significant expansion of its partnership with AstraZeneca (AZN). Under the terms of an amended oncology collaboration agreement, AstraZeneca has committed to paying Tempus AI $200 million over the next five years. The deal extends the existing relationship between the two companies, focusing on leveraging data and technology within the oncology space. This financial commitment provides Tempus AI with predictable long-term revenue while strengthening its position as a key data partner for major pharmaceutical players.

By https://seekingalpha.com/user/52867120/bio · Seeking Alpha ·

AstraZeneca Extends Oncology Collaboration with Tempus AI via $200M Agreement

Tickers: $AZN $TEM

Topics: biotechnology contract renewal oncology pharmaceuticals

Read the full article at Seeking Alpha

More World news